IGFBP2 Promotes Proliferation and Glycolysis of Endometrial Cancer by Regulating PKM2 / HIF ‐1α Axis
Cancer Science · 2025
DOI: 10.1111/cas.16447 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, 2025. Verfasst von Yuxi Jin und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China. Hauptthemen laut MEDLINE: Insulin-Like Growth Factor Binding Protein 2, Hypoxia-Inducible Factor 1, alpha Subunit, Thyroid Hormones, Endometrial Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Henan Provincial Key Project of Science and Technology Research, National Natural Science Foundation of China.
Abstract (Originalsprache)
Endometrial cancer (EC) is a worldwide gynecologic malignancies, with a remarking increase of incidence and mortality rates in recent years. Growing evidence indicates that glucose metabolism reprogramming is the most representative metabolic signature of tumor cells and exploring its modulatory function in EC development will promote identifying potential EC therapeutic targets. IGFBP2 is an insulin‐like growth factor binding protein which is closely associated with a variety of metabolic diseases. However, its biological role in EC and its effects on glucose metabolism remain unclear. In this study, we demonstrated that IGFBP2 was highly expressed in EC tissues and correlated with poor prognosis. Overexpression of IGFBP2 promoted proliferation and glycolysis in EC cells, whereas IGFBP2 knockdown had the opposite effect. Mechanistically, IGFBP2 directly interacted with PKM2, inducing weakened PKM2 protein degradation, and knockdown IGFBP2 expression prevented the translocation of PKM2 to the nucleus. Additionally, IGFBP2 expression was upregulated under the condition of hypoxia which directly regulated by transcriptional activation of HIF‐1α. Finally, the role of the IGFBP2/PKM2/HIF‐1α axis in EC tumor growth was confirmed in vivo using mouse xenograft models. Taken together, the current study identifies IGFBP2 as an upstream activator of PKM2‐driven proliferation and glycolysis in EC cells, providing a promising therapeutic target for EC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gynecology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
- Medical Key Laboratory for Prevention and Treatment of Malignant Gynecological Tumor, Zhengzhou, Henan, China.
- Laboratory Animal Center, State Key Laboratory of Esophageal Cancer Prevention & Treatment, Zhengzhou University, Zhengzhou, Henan, China.
ORCID-Profile: Yuxi Jin
Förderung
- Henan Provincial Key Project of Science and Technology Research
- National Natural Science Foundation of China
Zitieren
APA
Jin, Y., Qi, M., Si, L., Shi, X., Cai, M., Fu, H., Liu, Y., & Guo, R. (2025). IGFBP2 Promotes Proliferation and Glycolysis of Endometrial Cancer by Regulating PKM2 / HIF ‐1α Axis. Cancer Science. https://doi.org/10.1111/cas.16447
Vancouver
Jin Y, Qi M, Si L, Shi X, Cai M, Fu H, et al. IGFBP2 Promotes Proliferation and Glycolysis of Endometrial Cancer by Regulating PKM2 / HIF ‐1α Axis. Cancer Science. 2025. doi:10.1111/cas.16447
BibTeX
@article{Jin2025,
author = {Jin, Yuxi and Qi, Meng and Si, Lulu and Shi, Xiaojing and Cai, Mingbo and Fu, Hanlin and Liu, Yana and Guo, Ruixia},
title = {IGFBP2 Promotes Proliferation and Glycolysis of Endometrial Cancer by Regulating PKM2 / HIF ‐1α Axis},
journal = {Cancer Science},
year = {2025},
doi = {10.1111/cas.16447}
}
EUVIMED